Crosswalk Therapeutics develops therapies for rare genetic diseases by targeting clinically identified, genetically validated loss‑of‑function and toxic gain‑of‑function mechanisms. The company uses a modality‑neutral platform—protein, gene, RNA, or small‑molecule—to select the optimal therapeutic class for each target, focusing on patient convenience and rapid development across lysosomal storage, metabolic, hematology, and immunology indications.
Funding
Funding not disclosed
Founders
Product
Problem
Patients with rare genetic diseases often have limited or no approved treatments, leading to unmet medical needs and poor health outcomes. Developing therapies for these small, heterogeneous populations is challenging due to high scientific risk and the need for tailored therapeutic approaches.
Solution
Crosswalk Therapeutics addresses this gap by pursuing genetically validated targets that account for over 80% of rare diseases. The company develops functional replacement therapies for loss‑of‑function disorders and engineered solutions for toxic gain‑of‑function conditions, selecting the most appropriate modality—whether protein, gene, RNA, or small‑molecule—based on therapeutic requirements and patient convenience. By focusing on clinically identified and pre‑clinically validated targets, Crosswalk improves the probability of success and accelerates development timelines. Their expertise spans lysosomal storage diseases, inborn errors of metabolism, benign hematology, and immunology, enabling rapid entry into new disease areas. The platform emphasizes patient‑centric design, aiming to deliver treatments that are both effective and convenient for the rare disease community.
Target Audience
Primary customers are pharmaceutical and biotech companies seeking to develop or partner on rare disease therapies, as well as patient advocacy groups and healthcare providers focused on rare genetic conditions.
Features
- Modality‑neutral development pipeline that selects the optimal therapeutic class (protein, gene, RNA, or small‑molecule) for each target
- Genetically validated target selection leveraging the fact that >80% of rare diseases have a known genetic cause
- Strategies for both loss‑of‑function (functional replacement) and toxic gain‑of‑function (engineered inhibition) mechanisms
- Integrated expertise across multiple rare disease domains, including lysosomal storage, metabolic disorders, hematology, and immunology
- Patient‑focused approach that considers convenience and delivery method in therapy design